Advancing First-Line Treatment Strategies in Gastric and Esophageal Cancers
Panelists discuss how the 5-year survival data for nivolumab plus chemotherapy underscore its sustained efficacy as a first-line treatment, showing durable benefits over alternatives. Further research, including real-world evidence and broader clinical trials, is needed to validate its long-term impact across diverse patient populations and cancer subtypes.
EP: 1.Treatment Landscape and Unmet Needs in Advanced Gastric Cancers
EP: 2.CheckMate649 5-Year Follow-Up, Study Design, and Efficacy Results
EP: 3.Evaluating Long-Term Outcomes and Personalized Treatment Strategies in Advanced Gastrointestinal Cancers
EP: 4.Assessing the Long-Term Safety and Efficacy of Nivolumab Plus Chemotherapy for Broader Clinical Adoption in Advanced GI Cancers
EP: 5.Balancing Treatment Intensity, Quality of Life, and Biomarker-Driven Approaches in Advanced GI Cancers
Now Viewing
EP: 6.Advancing First-Line Treatment Strategies in Gastric and Esophageal Cancers
- What insights do the 5-year survival data for nivolumab plus chemotherapy provide when considering its efficacy alongside other first-line treatments for these cancers?
- What additional research or real-world evidence might be needed to further solidify the role of nivolumab plus chemotherapy based on these findings?
Recent Videos
Related Content
Efficacy and Safety of Zolbetuximab in Gastric Cancer
Aiman Waheed, MBBS;Muhammad Numan Saleem, MBBS;Yash Shah, MD;Muhammad Hamza Gul, MBBS, MD;Helai Hussaini, MD;Abdul Baseer Wardak, MBBS
December 6th 2024Article
Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
